ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May

Top Earnings Movers May 2025 Mid-Caps blurred - This image is an original composition by MarketBeat using licensed and editorial elements. Not for redistribution or reuse.

In May, three stocks that released earnings stood out due to their massive sales beats. These names are mid-cap companies with market capitalizations between $2 billion and $10 billion.

Companies of this size are typically less covered by Wall Street analysts, creating larger opportunities for earnings surprises. Indeed, these companies surprised, leading to huge moves in shares.

TMDX’s Sales Rout Forecasts, Boosts Full Year Guidance

[content-module:Forecast|NASDAQ: TMDX]

One stock that markets have had a love-hate relationship with over the last 52 weeks or so is TransMedics Group (NASDAQ: TMDX). The healthcare company has beaten sales estimates and seen shares rise afterward in three out of its last four releases. However, the one time that the company missed estimates over this period resulted in dire consequences for the stock.

After the company’s Q3 2024 release came out at the end of October 2024, shares dropped 30% in one day. 

Luckily for shareholders, TransMedics delivered in its latest release. The company’s Q1 2025 sales came in at over $143 million, around 16% higher than the $123 million analysts expected. This resulted in revenue growth of over 48%, massively faster than the approximately 27% analyst forecasts implied.

This revenue beat enabled the company to post adjusted earnings per share (EPS) of $0.70, more than twice the expected amount. TransMedics also increased the midpoint of its full-year revenue guidance by $34 million, adding fuel to its fire.

The company’s current full-year revenue forecast of $575 million implies growth of 30% compared to 2024. Shares rose nearly 20% in the day following the release. As of the June 10 close, the stock remains down around 20% from its all-time high closing price reached in August 2024.

ECG: +20% Sales Beat, Backlog Up 41% on Data Center Demand

[content-module:Forecast|NYSE: ECG]

Next up is Everus (NYSE: ECG). This mid-cap construction services stock also handily beat expectations on sales, posting revenue of nearly $827 million in Q1. This was around $150 million higher than forecasted, resulting in a sales beat of over 22%. Sales growth was 32%, approximately four times faster than the Wall Street-anticipated growth of 8%. Aided by this topline number, the company’s non-adjusted EPS rose by 31% to $0.72. Analysts thought the figure would decline by 22% to $0.43.

Shares rose 17% on the day after the results. Although analyst coverage on this stock is relatively light, those that do cover it see a solid amount of upside in shares. Stifel Nicolaus and DA Davidson both raised their targets after the results. The average of their targets is just under $70, implying upside in shares of 16% from their June 10 closing price.

Stifel noted the 41% increase in the company’s order backlog as a reason for boosting its target to $70. The company’s backlog of $3.1 billion is slightly more than all the revenue generated over the last 12 months. This should help give the company a revenue floor going forward, providing it with a solid opportunity to continue growing sales strongly.

The company’s Electrical and Mechanical (E&M) backlog grew particularly fast at 46%. This was largely due to demand from data center buildouts, showing that the company is participating in this growing part of the economy.

Excelerate’s LNG Business Booms in Q1

[content-module:Forecast|NYSE: EE]

Last up is Excelerate Energy (NYSE: EE). Excelerate works in the liquefied natural gas (LNG) industry. It has one of the largest fleets of floating storage and regasification units (FSRUs) in the world. FSRUs are massive vessels that can not only transport LNG but can also convert it back into gas and deliver it to land-based receiving terminals.

The company’s Q1 sales were $315 million, beating estimates of $208 million by over 51%. Revenues grew by over 57%, compared to expectations of just 4% growth. Shares rose 10% afterward.

Jefferies recently initiated the stock with a $39 price target, implying upside of nearly 27% from its June 10 closing price. This reflects the rising global demand for LNG and the expectation that the company’s vessels will receive more valuable contracts once their current agreements expire.

However, others fear that LNG supply will significantly outstrip demand by 2030. This would put downward pressure on prices, potentially hurting Excelerate's investment thesis.

Overall, these three stocks had some of the most impressive sales beats in the market in May. Everus stands out in particular due to its rapid backlog growth, which creates an opportunity for sustained sales growth going forward.

Where Should You Invest $1,000 Right Now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.